| Q34324861 | Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy |
| Q42226607 | Diagnosis of asymptomatic natalizumab-associated PML: are we between a rock and a hard place? |
| Q37206687 | Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients |
| Q45737722 | Disproportionality signal of progressive multifocal leukoencephalopathy: monoclonal antibodies versus other immunosuppressants |
| Q39046213 | Drug-induced progressive multifocal leukoencephalopathy in multiple sclerosis: European regulators' perspective |
| Q41393684 | Drug-induced progressive multifocal leukoencephalopathy: Lessons learned from contrasting natalizumab and rituximab. |
| Q48612438 | Early detection and favourable outcome of natalizumab-related progressive multifocal leukoencephalopathy (PML) in two multiple sclerosis patients |
| Q30276550 | Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue |
| Q39650695 | Innovative Digital Tools and Surveillance Systems for the Timely Detection of Adverse Events at the Point of Care: A Proof-of-Concept Study |
| Q39391443 | Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis |
| Q41745436 | MRI pattern in asymptomatic natalizumab-associated PML. |
| Q33754882 | Natalizumab in Multiple Sclerosis: Long-Term Management |
| Q26781389 | Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated Entities |
| Q30613846 | PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section |
| Q30235523 | Progressive multi-focal leucoencephalopathy - driven from rarity to clinical mainstream by iatrogenic immunodeficiency. |
| Q90286870 | Progressive multifocal leukoencephalopathy: A 25-year retrospective cohort study |
| Q38562161 | Strategy in Regulatory Decision-Making for Management of Progressive Multifocal Leukoencephalopathy. |
| Q26780412 | Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group |
| Q38815391 | Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs |